NASDAQ:SNTI • US81726A2096
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SENTI BIOSCIENCES HOLDINGS I (SNTI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-30 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-21 | Leerink Partners | Initiate | Outperform |
| 2025-10-14 | HC Wainwright & Co. | Initiate | Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-06 | Laidlaw & Co. | Initiate | Buy |
| 2025-05-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-12-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-08-15 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-03-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-03-23 | Chardan Capital | Maintains | Buy |
| 2023-01-30 | Chardan Capital | Maintains | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-12-16 | JP Morgan | Initiate | Neutral |
| 2022-10-07 | Morgan Stanley | Initiate | Equal-Weight |
| 2022-09-29 | B of A Securities | Initiate | Buy |
| 2022-09-23 | Chardan Capital | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.561M -40.25% | -100.00% | 22K | -100.00% | 10.455M | 45.101M 331.38% | 155.99M 245.87% | 322.59M 106.80% | 343.33M 6.43% | 379.24M 10.46% | ||
| EBITDA YoY % growth | -63.204M -4.15% | -56.888M 9.99% | -60.09M -5.63% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -66.765M -7.54% | -60.726M 9.05% | -63.727M -4.94% | -83.015M -30.27% | -99.763M -20.18% | -115.274M -15.55% | -94.262M 18.23% | -11.543M 87.75% | 143.65M 1,344.50% | N/A | N/A | |
| Operating Margin | -2,606.99% | N/A | -289,668.18% | N/A | N/A | -1,102.58% | -209.00% | -7.40% | 44.53% | N/A | N/A | |
| EPS YoY % growth | N/A 91.40% | N/A -848.26% | N/A 81.81% | -1.12 58.66% | -0.91 18.14% | -1.20 -31.84% | -1.03 14.83% | 0.15 114.43% | 2.42 1,534.48% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 | -0.28 49.61% | -0.33 52.20% | -0.22 58.94% |
| Revenue Q2Q % growth | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.279M 12.92% | -14.601M 13.08% | -15.477M 8.68% | -16.75M -23.31% |
All data in USD
10 analysts have analysed SNTI and the average price target is 11.22 USD. This implies a price increase of 1074.5% is expected in the next year compared to the current price of 0.9553.
SENTI BIOSCIENCES HOLDINGS I (SNTI) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of SENTI BIOSCIENCES HOLDINGS I (SNTI) is -0.37 USD and the consensus revenue estimate is 0 USD.
The consensus rating for SENTI BIOSCIENCES HOLDINGS I (SNTI) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.